Recent Surge: Rani Therapeutics Holdings, Inc. has seen a massive spike in attention on X following a reported 200-280% stock surge. This jump is tied to a $1.09 billion partnership deal with Chugai Pharmaceutical for their RaniPill technology. Posts on X highlight excitement over this validation of their oral biologics platform.
Financial Boost: Alongside the deal, a $60 million private placement has extended Rani’s cash runway into 2028. Discussions on X emphasize this as a strong signal of market confidence in the company’s future. The buzz continues as users track the stock’s momentum and volume spikes.
Note: This discussion summary was generated from an AI condensation of post data.
Rani Therapeutics Holdings, Inc. Insider Trading Activity
Rani Therapeutics Holdings, Inc. insiders have traded $RANI stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $RANI stock by insiders over the last 6 months:
- CONE INVESTMENTS LIMITED PARTNERSHIP SOUTH has made 0 purchases and 2 sales selling 5,923,000 shares for an estimated $15,711,314.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Rani Therapeutics Holdings, Inc. Hedge Fund Activity
We have seen 13 institutional investors add shares of Rani Therapeutics Holdings, Inc. stock to their portfolio, and 14 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 3,151,354 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,619,480
- ALPHABET INC. removed 448,492 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $230,480
- CITADEL ADVISORS LLC added 137,349 shares (+inf%) to their portfolio in Q2 2025, for an estimated $70,583
- CWA ASSET MANAGEMENT GROUP, LLC added 66,667 shares (+80.0%) to their portfolio in Q3 2025, for an estimated $33,320
- FOREFRONT WEALTH PARTNERS, LLC removed 65,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $33,403
- BLACKROCK, INC. added 55,069 shares (+86.6%) to their portfolio in Q2 2025, for an estimated $28,299
- WELL DONE, LLC added 52,014 shares (+inf%) to their portfolio in Q2 2025, for an estimated $26,729
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Rani Therapeutics Holdings, Inc. Analyst Ratings
Wall Street analysts have issued reports on $RANI in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/21/2025
- Oppenheimer issued a "Outperform" rating on 05/16/2025
To track analyst ratings and price targets for Rani Therapeutics Holdings, Inc., check out Quiver Quantitative's $RANI forecast page.
Rani Therapeutics Holdings, Inc. Price Targets
Multiple analysts have issued price targets for $RANI recently. We have seen 3 analysts offer price targets for $RANI in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Brandon Folkes from HC Wainwright & Co. set a target price of $11.0 on 10/21/2025
- Michael Okunewitch from Maxim Group set a target price of $10.0 on 10/20/2025
- Andreas Argyrides from Oppenheimer set a target price of $4.0 on 05/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
